Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Neuroimmunology: Phase II trial demonstrates efficacy of erythropoietin in optic neuritis.
Dimethyl fumarate for multiple sclerosis.
Effirma, Synthetic Biologics
Origin, fate and dynamics of macrophages at central nervous system interfaces.
Novel MS Drugs Advance
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
12th International Conference on Myasthenia Gravis and Related Disorders
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Brain and BrainPET 2015
Immune Tolerance and Autoimmune Disease Conference
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
[Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Influence of infection on exacerbations of multiple sclerosis.
Episode 33 with Dr. Pierre-Antoine Gourraud on the role of human leukocyte antigen in MS
AAN: Annual Meeting On Demand Encore: Treatment Optimization for Relapsing MS
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.

Pages